144 related articles for article (PubMed ID: 24808675)
1. Optimization of liposomal encapsulation for ceftazidime for developing a potential eye drop formulation.
Wijesooriya C; Budai M; Budai L; Szilasi ME; Petrikovics I
J Basic Clin Pharm; 2013 Jun; 4(3):73-5. PubMed ID: 24808675
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the
Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
[No Abstract] [Full Text] [Related]
5. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
6. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Richards DM; Brogden RN
Drugs; 1985 Feb; 29(2):105-61. PubMed ID: 3884319
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.
Neu HC; Labthavikul P
Antimicrob Agents Chemother; 1982 Jan; 21(1):11-8. PubMed ID: 6805421
[TBL] [Abstract][Full Text] [Related]
8. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.
Lagacé-Wiens P; Walkty A; Karlowsky JA
Core Evid; 2014; 9():13-25. PubMed ID: 24493994
[TBL] [Abstract][Full Text] [Related]
9. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
[TBL] [Abstract][Full Text] [Related]
10. Concentration-dependency of beta-lactam-induced filament formation in Gram-negative bacteria.
Buijs J; Dofferhoff AS; Mouton JW; Wagenvoort JH; van der Meer JW
Clin Microbiol Infect; 2008 Apr; 14(4):344-9. PubMed ID: 18261128
[TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
Zhanel GG; Lawson CD; Adam H; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Denisuik A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2013 Feb; 73(2):159-77. PubMed ID: 23371303
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
14. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
16. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
[TBL] [Abstract][Full Text] [Related]
17. Relation of structural properties of beta-lactam antibiotics to antibacterial activity.
Neu HC
Am J Med; 1985 Aug; 79(2A):2-13. PubMed ID: 3895915
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
19. [In vitro activity of ceftazidime compared with five beta-lactamase stable compounds against clinical strains of Acinetobacter calcoaceticus ].
Bergogne-Berezin E; Joly-Guillou ML; Verin-Prevost C
Pathol Biol (Paris); 1982 Jun; 30(6 Pt 2):506-9. PubMed ID: 6289227
[TBL] [Abstract][Full Text] [Related]
20. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).
Flamm RK; Farrell DJ; Sader HS; Jones RN
J Antimicrob Chemother; 2014 Jun; 69(6):1589-98. PubMed ID: 24562613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
